Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition LIBerateHoFH a phase 3 randomised openlabel crossover noninferiority trial

Simple item page
dc.article.end-page187en
dc.article.start-page178en
dc.citation.doi10.1016/S2213-8587(24)00313-9en
dc.contributor.authorFrederick Raalen
dc.contributor.authorVimal Mehtaen
dc.contributor.authorMeral Kayikciogluen
dc.contributor.authorD Blomen
dc.contributor.authorP Guptaen
dc.contributor.authorE et alen
dc.date.accessioned2025-11-13T08:53:52Z
dc.facultyFACULTY OF HEALTH SCIENCESen
dc.identifier.citationWOSen
dc.identifier.issn2213-8587en
dc.identifier.urihttps://hdl.handle.net/10539/47576
dc.journal.titleLerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition LIBerateHoFH a phase 3 randomised openlabel crossover noninferiority trialen
dc.journal.volume13en
dc.titleLerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition LIBerateHoFH a phase 3 randomised openlabel crossover noninferiority trialen
dc.typeJournal Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Journal Article.pdf
Size:
987.08 KB
Format:
Adobe Portable Document Format
Description:
Bitstream uploaded by REST Client
Download

Collections

Academic Wits Research Outputs (All submissions)